| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Kevin Caliendo maintains Cencora (NYSE:COR) with a Buy and raises the price target from $350 to $380.
Mizuho analyst Steven Valiquette maintains Cencora (NYSE:COR) with a Outperform and raises the price target from $316 to $334.
Biomarker data, enhanced therapeutic data and insights will enable biopharmaceutical innovation and physician support through i...